Cat. #153228
Anti-CD55 [BU84]
Cat. #: 153228
Sub-type: Primary antibody
Unit size: 100 ug
Availability: 3-4 weeks
Target: CD97 Ligand
Class: Monoclonal
Application: IHC
Reactivity: Human
Host: Mouse
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Margaret Goodall
Institute: University of Birmingham
Tool Details
*FOR RESEARCH USE ONLY
- Name: Anti-CD55 [BU84]
- Alternate name: Complement decay-accelerating factor 55; Dcay accelerating factor for complement; DAF
- Clone: BU84
- Tool sub type: Primary antibody
- Class: Monoclonal
- Conjugation: Unconjugated
- Strain: Balb/c
- Reactivity: Human
- Host: Mouse
- Application: IHC
- Description: CD55 regulates the complement system on the cell surface. It recognizes C4b and C3b fragments that are created during classical complement pathway and alternative complement pathway activation and indirectly blocks the formation of the membrane attack complex. CD97 is a member of the epidermal growth factor-seven transmembrane family. It affects tumour aggressiveness by binding its cellular ligand CD55 and exhibits adhesive properties. Previous studies have shown that CD97 and CD55 are involved in the dedifferentiation, migration, invasiveness and metastasis of tumours.
- Immunogen: Pre-B cells
- Isotype: IgG2a
Target Details
- Target: CD97 Ligand
- Target background: CD55 regulates the complement system on the cell surface. It recognizes C4b and C3b fragments that are created during classical complement pathway and alternative complement pathway activation and indirectly blocks the formation of the membrane attack complex. CD97 is a member of the epidermal growth factor-seven transmembrane family. It affects tumour aggressiveness by binding its cellular ligand CD55 and exhibits adhesive properties. Previous studies have shown that CD97 and CD55 are involved in the dedifferentiation, migration, invasiveness and metastasis of tumours.
Applications
- Application: IHC
Handling
- Format: Liquid
- Concentration: 0.9-1.1 mg/ml
- Unit size: 100 ug
- Storage buffer: PBS with 0.02% azide
- Storage conditions: -15° C to -25° C
- Shipping conditions: Shipping at 4° C
References
- Leucocyte Typing VI, (1998): edited by T. Kishimoto, Garland Publishing, New York.
- Ling et al. 1998. Clin Exp Immunol. 113(3):360-6. PMID: 9737663.
- Origin and properties of soluble CD21 (CR2) in human blood.
- Buescher et al. 1991. Public Health Rep. 106(3):333-8. PMID: 1905057.
- Problems in estimating the number of women in need of subsidized prenatal care.
